Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12436783 | 0.94 | CYP3A4 (0.38) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL12436929 | 0.81 | CYP3A4 (0.35) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL17066336 | 0.81 | CYP3A4 (0.44) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL17066337 | 0.81 | CYP3A4 (0.39) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL17066300 | 0.80 | CYP3A4 (0.45) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL12436925 | 0.80 | PREP (0.36) | — | |
| SCHEMBL17066342 | 0.80 | CYP3A4 (0.42) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL12437632 | 0.79 | CYP3A4 (0.35) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL12437414 | 0.78 | NR1I2 (0.30) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL12436388 | 0.78 | CYP3A4 (0.37) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011091532-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |